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and access, disparities, economics and decision modeling, 
trends in cancer outcomes, and health-related quality of life 
among target populations.  Conclusions: Ultimately, the suc-
cessful adoption of useful technologies will depend on un-
derstanding and influencing the patient, provider, health 
care system and societal factors that contribute to their up-
take and effectiveness in ‘real-world’ settings. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Within the past 30 years, extensive resources have 
been invested to develop cellular, molecular and genom-
ic (CMG) technologies with clinical applications that 
span the continuum of cancer care  [1] . The capacity for 
innovation stems largely from our rapidly expanding 
knowledge base in molecular carcinogenesis  [2] and bio-
technology. However, there are many challenges to trans-
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 Abstract 
 Background: In recent decades, extensive resources have 
been invested to develop cellular, molecular and genomic 
technologies with clinical applications that span the contin-
uum of cancer care.  Methods: In December 2006, the Na-
tional Cancer Institute sponsored the first workshop to 
uniquely examine the state of health services research on 
cancer-related cellular, molecular and genomic technolo-
gies and identify challenges and priorities for expanding the 
evidence base on their effectiveness in routine care.  Results: 
This article summarizes the workshop outcomes, which in-
cluded development of a comprehensive research agenda 
that incorporates health and safety endpoints, utilization 
patterns, patient and provider preferences, quality of care 
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lating this knowledge into clinically useful and well-im-
plemented interventions for cancer prevention, early de-
tection, diagnosis and treatment  [3] .
 The National Institutes of Health (NIH) have empha-
sized that translation and integration of new technologies 
are major priorities. Currently, 2 of 4 components in the 
NIH Core Strategic Vision directly address integration of 
research innovations into health care delivery, emphasiz-
ing the need to ‘accelerate translation of findings from the 
bench to the bedside to the community’ as well as ‘provide 
the evidence and knowledge base to allow for a rational 
transformation of our healthcare system’ (http://www.
nih.gov/about/director/newsletter/Spring2007.htm).
 In December 2006, the National Cancer Institute 
(NCI) sponsored the first workshop of researchers to fo-
cus on the delivery of CMG interventions in cancer care. 
The goals were to examine the current state of health 
 services research (HSR) on CMG interventions and to 
identify research priorities and challenges to expand our 
limited knowledge base about their effectiveness in ‘real-
world’ settings. Participants were primarily from aca-
demia and government, with expertise in HSR, including 
clinical decision making, economics, clinical and trans-
lational medicine, technology assessment, policy, and 
other areas. The workshop addressed cutting edge issues 
from a wide range of perspectives and also developed 
 recommendations for advancing a comprehensive HSR 
agenda on cancer-related CMG interventions. The objec-
tive of this report is to summarize the main workshop 
conclusions, beginning with a discussion of knowledge 
gaps surrounding the use of CMG interventions, followed 
by research needs and challenges, and ending with rec-
ommendations for a comprehensive HSR agenda to ad-
vance our understanding of their effectiveness. Several 
relevant areas are not addressed in this report because of 
limited coverage during the workshop. Their importance, 
however, is acknowledged in the section on workshop 
limitations.
 The Scope of HSR 
 HSR is defined by AcademyHealth (the primary pro-
fessional organization for HSR) as ‘the multidisciplinary 
field of scientific investigation that studies how societal 
factors, financing systems, organizational structures and 
processes, health technologies, and personal behaviors 
affect access to health care, the quality and cost of health 
care, and ultimately, our health and well-being’ (http://
www.academyhealth.org/about/whatishsr.htm). Box 1 
lists the main areas of HSR, as described by the Blue Cross 
Blue Shield Association (http://www.bcbs.com/about/
foundation/health-services-research-definition.html?
templateName=template-28719196&print=t).
 Box 1: Components of Health Services Research
 •  Costs, cost-effectiveness, cost-benefit and other eco-
nomic aspects of health care
 •  Patient and population health status/quality of life
 •  Outcomes of health care technologies/interventions 
 •  Practice patterns and diffusion of technologies/in-
terventions
•  Quality assurance programs/techniques designed to 
test generalizable attributes
 •  Guidelines, standards and criteria for health care
 •  Patient compliance with treatment
 •  Need and demand for health care
 •  Availability and accessibility of health care
 •  Utilization of health care
 •  Patient preferences for treatments, providers, set-
tings and so forth
 •  Organization and delivery of health care (for exam-
ple, managed care vs. fee for service)
 •  Health care workforce
 •  Financing of health care (for example, public and pri-
vate third-party payment, capitation)
•  Health care administration and management
 •  Health education and patient instruction
 •  Health professions education
 •  Health planning and forecasting
 •  Legal and regulatory changes affecting the health 
care system (for example, anti-trust laws) 
 •  Data and information needed for health care deci-
sion making (for example, report cards)
•  Studies of whether new health care technologies/in-
terventions (including randomized controlled trials) 
can produce a desired outcome in real-world settings 
of general or routine clinical practice
 The traditional methods employed in HSR to evaluate 
familiar interventions like mammography or chemo-
therapy are, for the most part, applicable to research on 
CMG technologies. However, the latter may have distin-
guishing features that require new methodologies or ad-
aptations to existing ones. Such features may include: 
limited insurance coverage (for example, genetic coun-
seling) and inadequate coding systems (for example, lab-
oratory genetic testing) that make it difficult to track or 
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identify an intervention in claims databases, the need to 
analyze and condense massive amounts of data points 
(for example, microarray-based gene polymorphism and 
expression assays), low power due to risk stratification of 
patients into multiple groups (for example, pharmacoge-
netics), rapid translation to clinical use with little clinical 
outcome data (for example, laboratory genetic testing), 
heightened concerns about genetic discrimination, and 
the complexities inherent to studying families rather 
than individuals (for example, predictive genetic testing 
for cancer risk assessment). Clearly, the strategies for HSR 
will vary by technology.
 The Scope of CMG Technologies in Cancer Care 
 Public and private funding has supported extensive 
research to develop a broad spectrum of CMG clinical 
applications, although progress has been uneven across 
cancer sites and technologies. Applications in cancer care 
range from primary prevention and early detection of 
malignancy to confirming diagnosis, selecting type and 
dose of treatment, and monitoring treatment effective-
ness. Commercially available tools for primary preven-
tion include predictive genetic tests for hereditary high-
risk mutations  [4] , nucleic acid and protein-based tests for 
oncogenic infectious agents  [5–7] , and recombinant pro-
phylactic vaccines against human papillomavirus  [8] and 
hepatitis B  [9] .
 There has also been considerable research on bio-
marker tests for early detection of cancer, where the chal-
lenges of developing highly sensitive and specific tests 
have limited the number of clinical applications current-
ly in practice  [10, 11] . A recent ‘horizon scan’ on genetic 
tests for cancer performed by the Agency for Healthcare 
Research and Quality (AHRQ) technology assessment 
program lists 11 screening tests that rely on DNA or pro-
tein-based technologies, including the widely used pros-
tate-specific antigen test (http://www.ahrq.gov/clinic/ta/
gentests/gentests.pdf).
 The majority of cancer biomarker tests, including 54 
listed in the AHRQ report, are used for the diagnosis and/
or treatment of cancer. Some diagnostic tests identify ab-
normal gene expression in tumors that may respond to 
targeted therapies, such as trastuzumab for HER2-posi-
tive breast cancers  [12] . The BCR-ABL gene test can be 
used to diagnose chronic myelogenous leukemia as well 
as monitor response to the tyrosine kinase inhibitor drug 
imatinib that targets the BCR-ABL  protein  [13] . Several 
gene expression-profiling tests detect and analyze pat-
terns of multiple genes expressed in early-stage breast tu-
mors, providing a prognostic score to identify potentially 
more aggressive tumors for which adjuvant chemothera-
py is indicated  [14, 15] . Other genetic tests identify germ-
line polymorphisms associated with drug toxicity or 
nonresponse, enabling early dose adjustment or selection 
of alternative therapies  [16, 17] .
 CMG applications also include targeted and support-
ive   therapies   to   treat   cancer.   Targeted   therapies,   such   as 
monoclonal antibodies or drugs, are designed to interfere 
with specific molecular pathways important to the growth 
and survival of tumor cells. Several targeted therapies that 
inhibit kinase enzyme activity (such as trastuzumab, ima-
tinib, erlotinib in epidermal growth factor receptor-posi-
tive non-small-cell lung cancer) have received Food and 
Drug Administration (FDA) approval and are in clinical 
use. Promising approaches to targeted drug delivery in-
clude chemotherapy molecules conjugated to natural or 
synthetic nanoparticles, which are efficiently taken up by 
tumor cells with fewer toxic side effects than drug formu-
lations requiring solvents  [18–20] . Supportive care thera-
pies, such as hematopoietic stem cell transplants and 
growth factor therapies, are used to replace stem cells or 
stimulate production of red and white blood cells de-
stroyed by chemotherapy or radiotherapy  [21–23] .
 Functional imaging and optical technologies have di-
verse applications, ranging from detection of early lesions 
and metastatic disease to monitoring response to treat-
ment. In vivo functional imaging techniques enable visu-
alization of molecular pathway activities, enhancing 
characterization of the disease state when used in con-
junction with structural imaging data  [24, 25] .
 Not unexpectedly, the number of CMG innovations in 
the developmental pipeline that are described in the lit-
erature exceeds the number currently used in clinical 
care. Although a strong scientific rationale often exists 
for their use, some technologies are not sufficiently de-
veloped to yield clinically useful results or improvements 
over existing interventions  [26] . Nevertheless, contextual 
factors, such as direct-to-consumer and provider market-
ing  [27, 28] , press coverage, or advocacy and lobbying ac-
tivities, may drive their diffusion into clinical practice 
before their safety and efficacy are well understood. 
 Gaps in Efficacy Research 
 A major concern for many emerging CMG interven-
tions is the limited amount of published premarketing 
clinical data about safety and efficacy, which provides the 
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basic evidence that new technologies have net benefit 
(that is, improve health outcomes). Premarketing safety 
and efficacy data are evaluated in technology assess-
ments, which are critical for decision making about ap-
propriate clinical uses of new technologies, coverage and 
reimbursement by insurers, and evidence-based guide-
lines. Technology assessments also identify existing gaps 
in both premarketing efficacy data and real-world effec-
tiveness data. Gaps in premarketing research on CMG 
technologies are summarized in box 2. Three areas with 
significant gaps include targeted therapies, screening in-
terventions and gene-based tests.
 Box 2: Research Gaps for CMG Technologies
Limited published data on analytic and clinical va-
lidity as well as clinical utility of diagnostic and predic-
tive tests, and devices:
• Lack of gold standards with which to assess analytic 
validity
• Studies of analytic validity often not published or 
otherwise publicly available
• Studies of clinical validity often small and not de-
signed to yield definitive results
• Studies on clinical utility (that is, impact of diagnos-
tic tests on subsequent treatment decisions or patient 
outcomes) seldom done
• In the United States, evidentiary standards for regu-
latory (that is, FDA) approval of laboratory tests and 
devices are less stringent than those for approval of 
therapeutics; in addition, laboratory tests may avoid 
FDA regulation entirely if developed in a laboratory 
and offered as a service by the same lab
Limited published randomized controlled trial data 
on safety and efficacy of therapeutics:
• Studies often have small sample size, restrictive in-
clusion criteria, short duration and surrogate out-
comes
• Concerns about market segmentation may serve as 
disincentives for conducting pharmacogenetic drug 
trials
Limited data on outcomes and effectiveness in rou-
tine clinical care:
• Standards of care needed in the early stages of diffu-
sion cannot be developed in the absence of clinical 
data
• Minimal HSR has been done to examine whether ap-
propriate levels of care are being provided, what the 
determinants are of disparities in outcomes and care, 
and what organizational or other changes are needed 
to optimize care
• Minimal surveillance has been conducted to monitor 
long-term outcomes of new interventions related to 
health, safety and quality of life
• Minimal economic studies have been done to assess 
incremental costs and cost-effectiveness of new tech-
nologies
 With respect to therapeutics, FDA approval requires 
data from randomized controlled trials (RCTs) to estab-
lish the safety and efficacy of new oncology drugs and 
biological therapies. Yet, RCTs of novel therapeutics often 
lack the power to detect uncommon adverse events and 
are not designed to assess off-label uses  [29] . Short trial 
duration and use of surrogate markers as primary end-
points can also limit understanding of therapeutic out-
comes. Furthermore, the generalizability of trial results 
may be affected by restrictive inclusion criteria that cause 
key demographic subgroups to be underrepresented. Un-
fortunately, these subgroups, such as elderly patients or 
those with comorbidities, may actually comprise a large 
proportion of users in routine care. In addition, incen-
tives to assess pharmacogenomic differences in drug re-
sponse may be tempered by industry concerns about 
market segmentation if fewer patients are found to ben-
efit from treatment  [30] .
 Gene-based tests to detect abnormalities in a single 
gene or a broader array of genes represent an area of 
growing importance for treatment decision making. Data 
from observational studies are typically used to obtain 
FDA approval for in vitro diagnostic test kits. However, 
laboratory-developed tests that are not marketed as kits, 
such as breast cancer (BRCA) tests for breast/ovarian 
cancer risk assessment and OncotypeDX TM for breast 
cancer prognosis, are not currently subject to FDA clear-
ance. In contrast to test kits, laboratory-developed tests 
may enter the market with minimal published informa-
tion about analytic and clinical validity  [31, 32] .
 With the widespread availability of different high-
throughput genomic and proteomic platforms and ana-
lytic techniques, and the lack of a gold standard for com-
parison to genomic expression data (or with current gold 
standards that are not adequately sensitive and/or spe-
cific), it can be difficult to establish analytic validity of a 
test. Furthermore, although the association of new bio-
markers with patient outcomes (that is, clinical validity) 
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often provides the incentive for test development, the pre-
dictive value of a test is likely to differ in high- versus low-
risk populations, thus requiring costly large samples to 
assess genetic, demographic or other variation. Other is-
sues can limit validation studies as well. As an example, 
a recent AHRQ evidence report on genomic tests for 
ovarian cancer found that studies had small sample sizes 
and spectrum biases, which affected the estimates of test 
sensitivity and specificity. These studies also had unre-
alistically high disease prevalence, which affected pre-
dictive value (http://www.ahrq.gov/clinic/tp/genovctp.
htm).
 Finally, validation studies alone cannot assess the clin-
ical utility of diagnostic tests, which addresses test impact 
on subsequent treatment decisions and patient outcomes. 
Most tests lack information on clinical utility when first 
introduced into clinical practice. The same AHRQ evi-
dence report on ovarian cancer found that the use of ge-
nomic tests to guide management decisions, and im-
provements in patient outcomes (compared to standard 
management), had not been evaluated in the context of 
diagnosis, or primary or secondary prevention. These 
limitations are not unique to genomic tests. Validation 
studies of optical technologies and molecular imaging 
devices also require costly large samples to examine 
sources of variability, and there are similar challenges to 
selecting appropriate gold standards and surrogate end-
points  [33, 34] .
 Gaps in Effectiveness Research 
 Even with promising premarket safety and efficacy 
data about many CMG interventions, the actual net ben-
efit observed in real-world settings is typically less than 
the expected net benefit obtained from RCTs, for several 
reasons. First, the former includes a more diverse, often 
sicker, patient population exhibiting less adherence and 
persistence with therapy, drug-drug interactions or phar-
macogenetic factors, and variations in delivery of care 
due to provider practices, coverage and reimbursement, 
or access. Furthermore, the short-term surrogate end-
points examined in RCTs may correlate imperfectly (or 
even poorly) with long-term health outcomes, especially 
if the natural history of the disease is not well understood 
or the clinical course is heterogeneous. The potential for 
differences between RCT and clinical practice results un-
derscores the need to monitor the effectiveness of CMG 
interventions in routine care. Research on effectiveness 
also evaluates whether appropriate care is being provided 
to those who need it, resulting in improved health and 
health-related quality of life.
 Gaps in effectiveness research are summarized in box 
2. For many CMG interventions, relatively few studies 
have examined uptake and patterns of care or associated 
clinical outcomes in routine care  [35] . Similarly, the in-
cremental costs, life expectancy and quality-adjusted life 
expectancy gains associated with CMG interventions, 
relative to clinical practice without their use, have not 
been evaluated; these will be necessary to conduct eco-
nomic evaluations, such as cost-effectiveness and cost-
utility analyses  [36] .
 One explanation for knowledge gaps about effective-
ness is that funded cancer research focusing on the deliv-
ery of CMG interventions has been minimal. In a search 
of the NCI cancer research portfolio database (http:// 
researchportfolio.cancer.gov/) from 2000 to 2006, only 
12 HSR or related grants were identified that focused on 
delivery of care involving CMG technologies [Ambs and 
Wideroff, pers. commun.]. These grants, which totaled 
USD 12 million, were found by independently entering 
19 biotechnology search terms (such as genetic tests, 
pharmacogenetics, biological therapies, cancer vaccines 
and nanotechnology) and restricting results to grants 
and contracts with research-type codes for patient care 
and survivorship, surveillance, cost analyses, health care 
delivery, education, communication, resources or infra-
structure. No additional grants were found when the 
search term ‘health disparities’ was added to each tech-
nology. One caveat is that projects conducted within large 
research infrastructures, such as cancer centers or P01 
grants, cannot be individually identified in abstracts, 
which possibly results in some underestimation. Never-
theless, to put this in perspective, total NCI research ex-
penditures for the same period were approximately USD 
18.29 billion (NCI Annual Fact Book, http://obf.cancer.
gov/financial/factbook.htm; see 2001 link: Total Research 
Grants, page 6/iv, for fiscal year 2000 and 2001 expendi-
tures; see 2003 link: Total Research Grants, page 7/v, for 
2002 and 2003; see 2004 link: Subtotal Research Grants, 
page 41/B-4, for 2004; see 2005 link: Subtotal Research 
Grants, pg. 53/B-4, for 2005; see 2006 link: Subtotal Re-
search Grants, page 53/B-4, for 2006).
 How to Address HSR Gaps 
 A strong HSR agenda is needed to evaluate clinical 
utility and reduce uncertainty about the net benefits of 
CMG interventions. Box 3 summarizes ways that HSR 
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can contribute to the knowledge base for CMG interven-
tions. The HSR agenda should include postmarketing 
surveillance to systematically monitor adverse events of 
new  therapies,  devices  and  tests.  Such  research   is   need-
ed to determine the balance of risks versus benefits of 
emerging CMG interventions among the heterogeneous 
populations that receive care in community settings 
(http://www.nap.edu/catalog.php?record_id=11897#toc). 
For example, postmarketing surveillance research has 
yielded valuable information about the risks and benefits 
of hematopoietic growth factors used in association with 
adjuvant chemotherapy  [37, 38] .
 Box 3: Ways to Address Research Gaps in CMG 
Technologies
Conduct postmarketing surveillance to systemati-
cally assess CMG technologies within well-defined tar-
get populations:
• Monitor clinical endpoints to assess safety and health 
outcomes
• Monitor patient-reported outcomes, such as func-
tional impact and psychosocial and economic bur-
den
Broaden research to evaluate the effectiveness and 
clinical utility of CMG technologies, by determining if 
appropriate care is being delivered to the target popula-
tions, with improvements in health and health-related 
quality of life:
• Assess prevalence and determinants of patient and 
provider use, knowledge, and attitudes
• Monitor trends in health plan and government poli-
cy toward coverage
• Determine economic impact, including incremental 
cost, cost-effectiveness and cost-utility
• Assess the multiple dimensions of access to care, par-
ticularly among medically underserved and target 
populations (that is, affordability, availability, ac-
ceptability, access by target populations, and accom-
modation of practice-to-patient constraints and pref-
erences)
• Determine the occurrence, determinants and conse-
quences of disparities in care, and test interventions 
to reduce or eliminate them
• Evaluate net benefit based on population trends in 
incidence, mortality, survival, and quality of life
Expand use of decision analysis in premarketing and 
postmarketing research to model the effectiveness of 
CMG technologies that add to or substitute existing 
standards of care:
• Change the model parameters to assess relative costs 
and benefits of interventions
• Compare interventions in populations with varying 
economic and health care resources and sociocultur-
al practices
 Yet, HSR must go well beyond postmarketing surveil-
lance to assess the adoption and impact of emerging 
CMG interventions at the patient, provider, health sys-
tem and population levels. A wide range of outcomes 
should be studied, including patient-reported quality of 
life indicators (such as functional impact, psychosocial 
and economic burden)  [39] , trends in patient and pro-
vider uptake and use, knowledge, attitudes and other de-
terminants that might facilitate or hinder adoption and 
appropriate use in specific settings  [40] , trends in health 
plan and government policy toward coverage and regula-
tion, incremental cost, cost-effectiveness and cost-utility 
 [41, 42] , and net benefit based on population trends in 
incidence, mortality, survival and quality of life  [43] .
 The knowledge obtained from this approach would be 
useful for defining standards of care and measuring the 
quality of care involving CMG interventions. In this re-
gard, the Institute of Medicine described 6 aims for health 
care: safety, effectiveness, patient-centeredness, timeli-
ness, efficiency and equity (http://www.iom.edu/CMS/
8089/5432.aspx). To measure how well those goals are 
 being met, a link must be made between a given process 
of care, such as administration of a genomic test or treat-
ment, and an outcome. These links can be difficult to 
establish. Additionally, the development and testing of 
quality measures is resource intensive, particularly for 
interventions that improve decision making and knowl-
edge (http://mdm.sagepub.com/content/vol27/issue5/) 
 [44, 45] . However, these links are essential for efficient 
identification, adoption and promotion of new CMG 
technologies that can positively impact patients’ lives.
 Access to health care will remain an important factor 
in improving overall population health care quality and 
outcomes. Broadly defined, access covers the dimensions 
of affordability, availability of services and their access by 
the target population, acceptability to patients, providers 
and the health care system, and accommodation of prac-
tice to patient constraints and preferences  [46, 47] . Al-
though there is currently little research about access to 
most CMG technologies, many of the issues are very rel-
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evant  [36] . High costs and limited insurance coverage 
may impose particular constraints on affordability. For 
example, biological therapies currently represent some of 
the highest expenditures in cancer treatment  [48] . The 
monoclonal antibody trastuzumab, indicated for meta-
static HER2-positive breast cancer  [49] , was estimated to 
cost USD 50,000 per year for a 70-kg woman  [50] , which 
potentially limits access for uninsured and underinsured 
patients.
 Availability of health services is another notable con-
straint to access, particularly for medical specialties with 
existing or projected work force supply deficits, such as 
genetic counseling and oncology  [51, 52] . With respect to 
genomic tests, it will be important to have access to high-
quality clinical labs that deliver results rapidly, so that the 
results can influence treatment decisions as near to real 
time as feasible. This is particularly challenging for sin-
gle-source tests offered by labs that conduct only 1 or a 
few tests and do not have an established shipping net-
work.  At the patient level, cultural and other factors, per-
haps undefined, may also influence access. One study 
noted a 5-fold higher uptake of genetic counseling for 
breast cancer 1 and 2 testing in white women, relative to 
African Americans, that was not explained by socioeco-
nomic or behavioral variables  [53] .
 Inequities in access to care due to socioeconomic, geo-
graphic, cultural, racial-ethnic or other factors can ulti-
mately lead to disparities in cancer incidence, mortality 
and health-related quality of life  [54] . Therefore, studies 
that describe the occurrence, determinants and conse-
quences of disparities, as well as those that test strategies 
to reduce or eliminate disparities, should be an integral 
part of an HSR agenda  [55] . Although some research has 
addressed disparities in genetic testing and follow-up 
care  [56] , little is currently known about disparities in 
utilization of most CMG technologies.
 Decision-analytic modeling can play an important 
role in evaluating the incremental costs and cost-effec-
tiveness of an emerging CMG intervention  [57] . In a 
model-based decision analysis, information about the 
disease, effectiveness of treatment, performance and 
costs of both new and existing technologies are combined 
with other relevant demographic and epidemiological 
characteristics of a target population. These models can 
be used to comparatively assess the relative costs and ben-
efits of technologies that add to or substitute existing 
standards of care  [58, 59] . Decision analysis can also be 
used to compare public health strategies in countries or 
populations with varying economic and health care re-
sources and sociocultural practices  [60] .
 Challenges in Addressing Gaps 
 Although the rationale to expand HSR on emerging 
CMG technologies is clear, there is less clarity about how 
to do this with the available resources. Administrative 
claims databases have been a mainstay of HSR  [61] , but 
may require substantial adaptations to accommodate 
CMG  information,  such  as:   specific   standardized   cod-
ing for new test procedures, and information on patient 
diagnosis and intent of the test; electronic linkages to ad-
ditional data sources; incorporation of genetic and fam-
ily history data. Cancer registries may need to be modi-
fied to allow their use for HSR research on CMG 
technologies, by incorporating data on tumor biomark-
ers, pharmacy claims and other data elements  [62] . Im-
ages and multiplex molecular test results may need to be 
incorporated into electronic medical records systems 
 [63] , which are already facing the complexities of interop-
erability across systems as well as tensions between pa-
tient privacy and accessibility to researchers  [64, 65] . The 
more expansive the data required to personalize care 
based on hereditary and molecular tumor characteris-
tics, the more complex and costly the data systems can 
become, with potentially long lag times required to im-
plement changes. Even with extensive informatics adap-
tations, some research questions can only be answered by 
collecting questionnaire data or other types of informa-
tion not recorded in the usual databases  [66] .
 Another challenge concerns selection of the appropri-
ate time to initiate HSR in the developmental trajectory 
of a new CMG technology. Unfortunately, the opportu-
nity to generate published HSR in the technical develop-
ment and testing phase is often missed because transla-
tional studies are typically restricted in scope and do not 
incorporate HSR disciplines  [67, 68] . Consequently, data 
that directly address health care delivery are often absent 
from translational medicine conferences and publica-
tions. Several conceptual models have described the 
translation of emerging CMG technologies into health 
practice, emphasizing the continuum of translational re-
search that could incorporate HSR at various stages  [68, 
69] . Certain types of HSR, such as decision analysis and 
assessment of quality of life and acceptability, could be 
readily integrated into premarket clinical studies. In fact, 
decision-analytic models can be used to extend the 
knowledge from empirical studies of CMG technologies 
to a broader array of clinical situations, and can allow for 
the extrapolation of costs and health effects beyond the 
time horizon of a single study. Models can formally relate 
biological and clinical information, provide quantitative 
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insight into the relative importance of different uncertain 
variables, and investigate how results will change if val-
ues of key parameters are changed. By identifying the 
most influential parameters, they can be used to help pri-
oritize and guide data collection efforts as well as assist 
with the design of randomized trials  [70] .
 Data on costs can certainly be collected during clinical 
trials, although the highly controlled experimental con-
ditions may not mirror the real-world practice conditions 
needed for economic analyses  [71] . Model-based analyses 
inevitably rely on uncertain assumptions and parame-
ters; as such, it is imperative that analysts be as transpar-
ent as possible and assess the impact of parameter and 
model uncertainty. The purpose and stage of develop-
ment of CMG technologies will greatly influence the eco-
nomic evaluation, due to differences in target popula-
tions, amount of available data on clinical outcomes and 
other variables of interest  [72] . Standardization of cost 
measures and analytic methods can ensure better com-
parability across economic studies  [73] .
 Incorporation of HSR into premarket clinical studies, 
and early in the diffusion curve when clinical guidelines 
and public health policies are nascent, can best be achieved 
through a scientific, team-based approach that brings to-
gether collaborating experts in translational and applied 
research. Early collaboration could facilitate timely mod-
ifications of databases used for postmarketing surveil-
lance to rapidly respond to information needs. Challeng-
es to implementing a transdisciplinary team approach 
include cross-disciplinary differences in terminology 
and research culture, complexities in working across in-
stitutions, and competing needs of tenure-track investi-
gators to obtain grants and publications in their own spe-
cific fields  [74, 75] . Also, due to increasing data complex-
ity, the teams may require expansion to include disciplines 
not previously considered, such as bioinformatics, sys-
tems biology and the social sciences.
 Understanding the use and impact of CMG technol-
ogies among medically underserved populations, such 
as racial or ethnic minorities and the uninsured, pre-
sents further challenges. These populations are often 
underrepresented in research due to limited access to 
health care, prioritization of social needs such as food 
or housing, distrust in the health care system, or other 
factors  [76–78] . Tailored and community-based ap-
proaches to recruiting may improve representation in 
various types of research  [79] . Inclusion of underserved 
populations in basic and translational cancer research 
can help ensure that HSR addresses relevant questions 
about health disparities. This is particularly important 
when the underserved populations are at highest risk of 
incidence and/or mortality, as is well-illustrated in the 
case of African American men and prostate cancer 
 [80] .
 CMG technologies are evolving in a changing regula-
tory and policy environment that may or may not facili-
tate HSR  [81] . Regulatory changes favoring pharmacoge-
nomic information on drug labels may lead to increased 
opportunities for collaborative HSR. In contrast, exclu-
sion of interventions such as genetic counseling and test-
ing from insurance coverage limits availability of data in 
claims databases. Ultimately, the growth of HSR on CMG 
technologies hinges on its perceived importance, the 
availability of interested research groups and funding re-
sources.
 One of the greatest challenges to expanding HSR is 
constrained government funding  [82] . Creative mecha-
nisms for funding HSR research, such as public-private 
partnerships or interagency federal initiatives, must be 
explored during this period of tightened budgets. Fur-
thermore, funding agencies should promote initiatives 
that specifically prioritize health care delivery research 
on CMG technologies, in both the translational and post-
marketing phase. The NIH program announcement, 
‘Understanding the Effects of Emerging Cellular, Molec-
ular, and Genomic Technologies on Cancer Health Care 




 In addition, AHRQ has started a new DEcIDE (Devel-
oping Evidence to Inform Decisions about Effectiveness) 
research network as part of its Effective Health Care pro-
gram to conduct accelerated studies about the outcomes, 
comparative clinical effectiveness, safety and appropri-
ateness of health care services (http://effectivehealthcare.
ahrq.gov/aboutUs.cfm?abouttype=decidecert). AHRQ 
has also recently solicited proposals to fund demonstra-
tion projects that advance understanding of how best to 
incorporate  clinical  decision  support  into  the   delivery  
of health care (http://www.fbo.gov/spg/HHS/AHRQ/
DCM/AHRQ%2D07%2D10045/Attachments.html). 
Such projects could specifically address funding needs 
for emerging CMG interventions. Since the workshop de-
scribed in this article, the Centers for Disease Control 
and Prevention National Office of Public Health Genom-
ics released several other relevant funding initiatives, un-
der the Genomic Applications in Practice and Prevention 
program, including one entitled ‘Translation Research’ 
(http://www.cdc.gov/od/pgo/funding/GD08-001.htm) 
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• Administrative databases of patient records should 
be systematically evaluated and modified to include 
infrastructure, data elements and electronic linkages 
that facilitate HSR. Standard HSR data sources may 
need modifications to be effectively used.
• Funding agencies and investigators should explore 
ways to further transdisciplinary team science that 
bridges discovery, development and delivery re-
search.
• Funding agencies and researchers should explore 
ways to fund HSR, with creative approaches empha-
sized during times of budget restrictions. Mecha-
nisms for priority funding should be considered to 
encourage HSR in both pre- and postmarketing stud-
ies. 
 A transdisciplinary team science approach can help 
ensure that these critical research needs are met. Certain 
areas, such as evaluation of patient and provider prefer-
ences as well as decision-analytic modeling, can be suc-
cessfully incorporated into both pre- and postmarketing 
clinical research. Other areas, such as utilization, access 
to care and population trends in cancer outcomes are in-
herently suited for the postmarketing phase. Adaptations 
may be needed to effectively use standard HSR data 
sources, such as claims databases, population-based can-
cer registries and health systems’ electronic medical 
 records.
 Workshop Limitations 
 Given time limitations, some areas were not addressed 
but should be a focus of further research. Although evi-
dence synthesis and its application in practice are valid 
forms of HSR, the workshop and its recommendations fo-
cused mostly on the primary research enterprise that al-
lows data to be collected for this purpose. Other areas that 
were not covered include dissemination and communica-
tions research, the role of practical clinical trials in build-
ing the evidence base for technology assessment  [83] , and 
reimbursement policy where evidence is limited. Interna-
tional comparisons were also not addressed, but could 
shed light on variability in adoption and effectiveness of 
CMG technologies in countries with different research 
priorities, clinical practices and health care systems. Spe-
cific bioinformatics tools, such as natural language pro-
cessing, were not discussed in detail, although such tools 
may be critical to improving the availability and validity 
of electronic medical records for HSR on emerging CMG 
and a second one entitled ‘Translation Programs in Edu-
cation, Surveillance, and Policy’ (http://www.cdc.gov/od/
pgo/funding/GD08-801.htm).
 Recommendations for Advancing HSR on CMG 
Technologies 
 Box 4 summarizes the recommendations of workshop 
participants for strengthening HSR on emerging CMG 
technologies, with recognition that specific strategies de-
pend on the type of technology and its stage of develop-
ment. HSR should systematically examine the benefits 
and harms of CMG technologies in routine clinical care. 
A wide range of outcomes must be studied, including 
preferences, utilization, access and disparities, quality of 
care, cost as well as trends in incidence, mortality, sur-
vival and health-related quality of life among target pop-
ulations. Demographically and biologically heteroge-
neous populations must be studied, using tailored com-
munity-based approaches to facilitate recruitment of the 
medically underserved.
 Box 4: A Proposed Health Services Research 
Agenda for CMG Technologies
• Certain HSR areas, such as assessment of patient and 
provider preferences, patient-reported outcomes, 
economic modeling and decision analysis, should be 
routinely incorporated in the premarketing phases of 
product development and efficacy testing. The meth-
odologies should be transparent, and the findings 
should be made publicly available. 
• Outcomes should include: patient-reported quality 
of life indicators; prevalence and determinants of 
 patient and provider use, knowledge, and attitudes; 
health plan and government policy toward coverage 
and regulation; incremental cost, cost-effectiveness 
and cost-utility; net benefit based on population 
trends in incidence, mortality, survival and quality 
of life. 
• Disparities in access to care and health outcomes 
should be routinely monitored, with special attention 
given to inclusion of racial/ethnic minorities and 
other underserved populations in studies. 
• A full range of outcomes should be considered when 
developing and evaluating quality measures of prog-
ress related to CMG technologies. 
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technologies. Institutional review board and privacy pol-
icies were not addressed in depth, although their impact 
on the research climate is significant.
 Conclusions 
 This workshop identified a comprehensive research 
agenda to better understand the delivery of care for 
emerging CMG interventions. Meaningful expansion of 
HSR on CMG technologies hinges on its perceived im-
portance, the availability of interested research groups 
and funding resources. Ultimately, the successful adop-
tion of appropriate technologies will depend on under-
standing and informing the patient, provider, health care 
system as well as societal factors that contribute to effec-
tiveness and uptake in routine clinical care.
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